{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:35Z","timestamp":1789674515057,"version":"4.0.1"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamaneurol.2018.0094","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T12:31:20Z","timestamp":1520857880000},"page":"827","source":"Crossref","is-referenced-by-count":46,"title":["Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis"],"prefix":"10.1001","volume":"75","author":[{"given":"Martijn T.","family":"Wijburg","sequence":"first","affiliation":[{"name":"Department of Neurology, Neuroscience Amsterdam, VUmc Multiple Sclerosis Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kleerekooper","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuroscience Amsterdam, VUmc Multiple Sclerosis Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Radiology and Nuclear Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I.","family":"Lissenberg-Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlieke","family":"de Vos","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Department of Neurology, Medical Faculty, University of K\u00f6ln, K\u00f6ln, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M. J.","family":"Uitdehaag","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuroscience Amsterdam, VUmc Multiple Sclerosis Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuroscience Amsterdam, VUmc Multiple Sclerosis Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Neuroscience Amsterdam, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi180005r1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"noi180005r2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi180005r3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond.","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"},{"issue":"15","key":"noi180005r4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"noi180005r5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"noi180005r6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00415-013-7191-9","article-title":"Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.","volume":"261","author":"Havla","year":"2014","journal-title":"J Neurol"},{"issue":"7","key":"noi180005r7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","article-title":"Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.","volume":"78","author":"Blair","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"noi180005r8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/WNL.0b013e31826846b4","article-title":"The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?","volume":"79","author":"Phan-Ba","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"noi180005r9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"noi180005r10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"issue":"14","key":"noi180005r11","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"noi180005r12","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"noi180005r13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients.","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"noi180005r14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis.","volume":"37","author":"Traboulsee","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"noi180005r15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","article-title":"Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?","volume":"261","author":"Wattjes","year":"2014","journal-title":"J Neurol"},{"issue":"23","key":"noi180005r16","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","article-title":"Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.","volume":"77","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"noi180005r17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/1352458515615225","article-title":"Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.","volume":"22","author":"Wattjes","year":"2016","journal-title":"Mult Scler"},{"issue":"8","key":"noi180005r18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","article-title":"MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.","volume":"87","author":"Wattjes","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"noi180005r19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML.","volume":"86","author":"Wattjes","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi180005r20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"noi180005r21","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","article-title":"MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.","volume":"87","author":"Wijburg","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"noi180005r22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00415-015-8001-3","article-title":"Concomitant granule cell neuronopathy in patients with natalizumab-associated PML.","volume":"263","author":"Wijburg","year":"2016","journal-title":"J Neurol"},{"issue":"3","key":"noi180005r23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1148\/radiol.2015150673","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging.","volume":"278","author":"Hodel","year":"2016","journal-title":"Radiology"},{"issue":"7","key":"noi180005r24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"noi180005r25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"Suppl. 4","key":"noi180005r26","first-page":"27","article-title":"Imaging findings for PML in natalizumab-treated MS patients.","volume":"18","author":"Richert","year":"2012","journal-title":"Mult Scler"},{"issue":"12","key":"noi180005r27","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/340535","article-title":"JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions.","volume":"34","author":"Garc\u00eda De Viedma","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"noi180005r28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"issue":"6","key":"noi180005r29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/1352458516667241","article-title":"Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"23","author":"Hoepner","year":"2017","journal-title":"Mult Scler"},{"issue":"4","key":"noi180005r30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes.","volume":"19","author":"Clifford","year":"2013","journal-title":"J Neurovirol"},{"issue":"6","key":"noi180005r31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"issue":"12","key":"noi180005r32","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/jnnp-2016-315298","article-title":"Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"88","author":"Warnke","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2674280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T12:34:01Z","timestamp":1531139641000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.0094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.0094","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}